Cat. No.
MABL-696
Application
immunotherapy, inhibit, ELISA
Isotype
Engineer antibody
Species Reactivity
Marmoset, Human, Cynomolgus Monkey
Clone No.
1A11 H3L4
From
Recombinant Antibody
Specificity
This antibody binds the alpha component of the human IL-7RA (CD127). This antibody also cross reacts with cynomolgus monkey and marmoset IL-7Ra. This protein acts as a receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). Binding of IL-7 to the IL-7R activates multiple signaling pathways including the activation of JAK kinases 1 and 3 leading to the phosphorylation and activation of Stat5. Another IL-7R mediated pathway is the activation of PI3 kinase, resulting in the phosphorylation of the pro-apoptotic protein Bad and its cytoplasm retention. CD127 is expressed in peripheral resting and memory T cells.
Alternative Names
IL7R; IL-7RA; CDw127; Interleukin-7 receptor subunit alpha; IL-7 receptor subunit alpha; IL-7R subunit alpha; IL-7R-alpha; GSK2618960
UniProt
P16871
Immunogen
The original parental mouse antibody1A11 was generated by immunizing C57BL/6 mice with a synthetic peptide (300 μg) of myelin oligodendrocyte glycoprotein (MOG residues 35-55). This antibody is a humanized and affinity matured version of 1A11.
Application Notes
The binding affinity of this antibody for human interleukin 7 receptor was determined using BIACORE analysis and was reported to be Kd= 22 pM. This antibody demonstrated complement dependent cytotoxicity on HEK293 cells expressing hIL-7R in vitro. This antibody showed inhibition of IL-7- induced STAT5 phosphorylation in human polymorphonuclear monocytes and IL-17 production in differentiated human Th17 cells in an in vitro assay (US9150653). The safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of this antibody was studied in healthy subjects.
Single doses of this antibody (0.6 mg kg–1 or 2.0 mg kg–1) were well tolerated, increased circulating IL‐7 and soluble CD127, and elicited antidrug antibodies with neutralizing capability, but did not have an impact on lymphocyte populations, inflammatory cytokines or differentiation markers. It blocked IL-7 receptor signaling upon full target engagement. This antibody may effectively modulate the autoinflammatory activity of pathogenic T cells in diseased tissue (PMID: 30161291). The characterization of humoral
response generated after administration of this antibody was studied in a single-dose escalation phase I study (PMID: 33755713).
Antibody First Published
Ellis et al. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2019 Feb;85(2):304-315. PMID:30161291
Note on publication
This paper investigates the safety, pharmacokinetics, pharmacodynamics and immunogenicity of this antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
